American Cancer Society
The Lifetime Probability of Developing and Dying from Cancer, 2007-2009*

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in…	%	1 in…	%	1 in…	%	1 in…
All Sites†	44.81	2	23.08	4	38.17	3	19.39	5
Brain & ons	0.70	144	0.50	201	0.55	181	0.40	252
Breast	0.13	781	0.03	3,142	12.38	8	2.76	36
Colorectal	5.17	19	2.11	47	4.78	21	1.94	51
Esophagus	0.81	124	0.78	127	0.23	427	0.21	480
Hodgkin lymphoma	0.25	401	0.04	2,253	0.21	476	0.04	2,757
Kidney & renal pelvis	2.04	49	0.61	164	1.20	83	0.34	291
Larynx	0.60	166	0.21	475	0.14	736	0.05	1,873
Leukemia	1.59	63	1.02	98	1.14	88	0.71	140
Liver & intrahepatic bile duct	1.18	85	0.83	120	0.49	202	0.43	231
Lung & bronchus	7.77	13	6.74	15	6.35	16	5.02	20
Melanoma of skin‡	2.87	35	0.48	209	1.85	54	0.23	426
Myeloma	0.77	129	0.46	215	0.57	175	0.37	274
Non-Hodgkin lymphoma	2.34	43	0.88	114	1.93	52	0.71	141
Oral cavity & pharynx	1.50	66	0.38	263	0.68	148	0.18	548
Ovary	NA	NA	NA	NA	1.38	72	1.00	100
Pancreas	1.48	67	1.32	76	1.45	69	1.30	77
Prostate	16.15	6	2.75	36	NA	NA	NA	NA
Stomach	1.09	92	0.51	195	0.66	151	0.34	298
Testis	0.37	268	0.02	5,420	NA	NA	NA	NA
Thyroid	0.52	191	0.05	1,865	1.53	65	0.07	1,433
Urinary bladder§	3.81	26	0.88	114	1.15	87	0.34	296
Uterine cervix	NA	NA	NA	NA	0.68	147	0.23	433
Uterine corpus	NA	NA	NA	NA	2.64	38	0.54	185

* For those free of cancer at beginning of age interval.

† All sites excludes basal and squamous cell skin cancers and in situ cancers except urinary bladder.

‡ Statistics are for whites.

§ Includes invasive and in situ cancer cases.

NA=Not applicable.

Source: Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.6.1, National Cancer Institute, 2012.

American Cancer Society, Surveillance Research, 2013